PCSA
Processa Pharmaceuticals, Inc.
Latest Form 4:Purchase$4KbyLin Patrick (Chief Business - Strategy Off) · filed Jul 1, 2026
Processa Pharmaceuticals, Inc. (PCSA) has 54 SEC Form 4 filings (54 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 11, 2026.
Inside the rolling window, 9 insiders at Processa Pharmaceuticals, Inc. reported 41 open-market purchases totaling $209K and no open-market sales. The most active filer is Chief Business - Strategy Off Lin Patrick with 7 filings. Insiders have net bought $209K over the trailing 6 months. The most recent open-market filing is a purchase of 2,106 shares by Chief Business - Strategy Off Lin Patrick, dated Jun 30, 2026, worth $4K.
- Industry:Biotechnology
- CEO:George K. Ng
- Employees:10
- HQ:Hanover, MD, US
- IPO:2014-03-07
Insider Buying
$209K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$5.8M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Business - Strategy Off | Purchase | 2,106 | $4K | Jul 1 | SEC ↗ | |
| Chief Financial Officer | Purchase | 3,277 | $6K | Jul 1 | SEC ↗ | |
| Pres. Research & Development | Purchase | 2,531 | $5K | Jul 1 | SEC ↗ | |
| Chief Executive Officer | Purchase | 3,057 | $6K | Jul 1 | SEC ↗ | |
| Chief Administrative Officer | Purchase | 2,436 | $5K | Jul 1 | SEC ↗ | |
| Chief Business - Strategy Off | Purchase | 1,831 | $4K | Jun 16 | SEC ↗ | |
| Pres. Research & Development | Purchase | 2,067 | $5K | Jun 16 | SEC ↗ | |
| Chief Financial Officer | Purchase | 2,654 | $6K | Jun 16 | SEC ↗ | |
| Chief Executive Officer | Purchase | 2,465 | $5K | Jun 16 | SEC ↗ | |
| Chief Administrative Officer | Purchase | 2,118 | $5K | Jun 16 | SEC ↗ | |
| Chief Executive Officer | Purchase | 2,129 | $5K | Jun 1 | SEC ↗ | |
| Chief Business - Strategy Off | Purchase | 1,582 | $4K | Jun 1 | SEC ↗ | |
| Chief Administrative Officer | Purchase | 1,829 | $5K | Jun 1 | SEC ↗ | |
| Chief Financial Officer | Purchase | 2,292 | $6K | Jun 1 | SEC ↗ | |
| Pres. Research & Development | Purchase | 1,786 | $5K | Jun 1 | SEC ↗ | |
| Chief Business - Strategy Off | Purchase | 1,369 | $4K | May 19 | SEC ↗ | |
| Chief Financial Officer | Purchase | 1,984 | $6K | May 19 | SEC ↗ | |
| Pres. Research & Development | Purchase | 1,545 | $5K | May 19 | SEC ↗ | |
| Chief Administrative Officer | Purchase | 1,583 | $5K | May 19 | SEC ↗ | |
| Chief Executive Officer | Purchase | 1,843 | $5K | May 19 | SEC ↗ | |
| Chief Executive Officer | Purchase | 1,843 | $5K | May 19 | SEC ↗ | |
| Chief Development Officer | Purchase | 3,957 | $11K | May 19 | SEC ↗ | |
| Chief Business - Strategy Off | Purchase | 1,511 | $4K | May 1 | SEC ↗ | |
| Chief Administrative Officer | Purchase | 1,748 | $5K | May 1 | SEC ↗ | |
| Chief Executive Officer | Purchase | 2,034 | $5K | May 1 | SEC ↗ | |
| Chief Financial Officer | Purchase | 2,190 | $6K | May 1 | SEC ↗ | |
| Pres. Research & Development | Purchase | 1,706 | $5K | May 1 | SEC ↗ | |
| Chief Executive Officer | Purchase | 2,136 | $5K | Apr 30 | SEC ↗ | |
| Chief Business - Strategy Off | Purchase | 1,369 | $4K | Apr 17 | SEC ↗ | |
| Chief Development Officer | Purchase | 1,799 | $5K | Apr 17 | SEC ↗ | |
| Pres. Research & Development | Purchase | 1,545 | $5K | Apr 17 | SEC ↗ | |
| Chief Financial Officer | Purchase | 1,984 | $6K | Apr 17 | SEC ↗ | |
| Chief Administrative Officer | Purchase | 1,583 | $5K | Apr 17 | SEC ↗ | |
Neal James RFirst filing | Director | Purchase | 789 | $2K | Apr 2 | SEC ↗ |
Lin PatrickFirst filing | Chief Business - Strategy Off | Purchase | 1,603 | $4K | Apr 1 | SEC ↗ |
Pannu GeraldineFirst filing | Director | Purchase | 2,072 | $5K | Apr 1 | SEC ↗ |
Baluch KhosoFirst filing | Director | Purchase | 2,269 | $6K | Apr 1 | SEC ↗ |
Young DavidFirst filing | Pres. Research & Development | Purchase | 1,810 | $5K | Apr 1 | SEC ↗ |
SKIBSTED RUSSELLFirst filing | Chief Financial Officer | Purchase | 2,324 | $6K | Apr 1 | SEC ↗ |
Bigora SianFirst filing | Chief Development Officer | Purchase | 2,107 | $5K | Apr 1 | SEC ↗ |
Guy WendyFirst filing | Chief Administrative Officer | Purchase | 1,854 | $5K | Apr 1 | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does PCSA have?
Processa Pharmaceuticals, Inc. (PCSA) has 54 SEC Form 4 filings (54 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Aug 11, 2026.
When was the most recent SEC Form 4 filing for PCSA?
The most recent Form 4 filing for PCSA on Tracefour is dated Aug 11, 2026.
Who is the most active insider at PCSA?
The most active SEC Form 4 filer at PCSA in the rolling window is Chief Business - Strategy Off Lin Patrick, with 7 filings.
What is the net insider flow at PCSA over the last 6 months?
Over the trailing 180 days, insiders at PCSA have net bought $209K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at PCSA in the current window?
Inside the rolling window, insiders at PCSA bought $209K and sold $0 based on SEC Form 4 filings.
Can I get alerts for PCSA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Processa Pharmaceuticals, Inc. (PCSA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Processa Pharmaceuticals, Inc. is in the Healthcare sector.